1. Market Research
  2. > Viral Infections – Pipeline Review, H1 2013

Viral Infections – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 739 pages

Viral Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Viral Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Viral Infections. Viral Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Viral Infections.
- A review of the Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Viral Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Viral Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Viral Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Viral Infections - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 13
Viral Infections Overview 14
Therapeutics Development 15
Viral Infections Therapeutics under Development by Companies 17
Viral Infections Therapeutics under Investigation by Universities/Institutes 40
Late Stage Products 45
Mid Clinical Stage Products 46
Early Clinical Stage Products 47
Discovery and Pre-Clinical Stage Products 48
Viral Infections Therapeutics - Products under Development by Companies 49
Viral Infections Therapeutics - Products under Investigation by Universities/Institutes 91
Companies Involved in Viral Infections Therapeutics Development 97
Viral Infections - Therapeutics Assessment 354
Drug Profiles 362
Viral Infections Therapeutics - Drug Profile Updates 579
Viral Infections Therapeutics - Discontinued Products 664
Viral Infections Therapeutics - Dormant Products 674
Viral Infections - Product Development Milestones 711
Appendix 720

List of Tables

Number of Products Under Development for Viral Infections, H1 2013 33
Products under Development for Viral Infections - Comparative Analysis, H1 2013 34
Number of Products under Development by Companies, H1 2013 36
Number of Products under Development by Companies, H1 2013 (Contd..1) 37
Number of Products under Development by Companies, H1 2013 (Contd..2) 38
Number of Products under Development by Companies, H1 2013 (Contd..3) 39
Number of Products under Development by Companies, H1 2013 (Contd..4) 40
Number of Products under Development by Companies, H1 2013 (Contd..5) 41
Number of Products under Development by Companies, H1 2013 (Contd..6) 42
Number of Products under Development by Companies, H1 2013 (Contd..7) 43
Number of Products under Development by Companies, H1 2013 (Contd..8) 44
Number of Products under Development by Companies, H1 2013 (Contd..9) 45
Number of Products under Development by Companies, H1 2013 (Contd..10) 46
Number of Products under Development by Companies, H1 2013 (Contd..11) 47
Number of Products under Development by Companies, H1 2013 (Contd..12) 48
Number of Products under Development by Companies, H1 2013 (Contd..13) 49
Number of Products under Development by Companies, H1 2013 (Contd..14) 50
Number of Products under Development by Companies, H1 2013 (Contd..15) 51
Number of Products under Development by Companies, H1 2013 (Contd..16) 52
Number of Products under Development by Companies, H1 2013 (Contd..17) 53
Number of Products under Development by Companies, H1 2013 (Contd..18) 54
Number of Products under Development by Companies, H1 2013 (Contd..19) 55
Number of Products under Development by Companies, H1 2013 (Contd..20) 56
Number of Products under Development by Companies, H1 2013 (Contd..21) 57
Number of Products under Investigation by Universities/Institutes, H1 2013 59
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 60
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 61
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 62
Comparative Analysis by Late Stage Development, H1 2013 63
Comparative Analysis by Mid Clinical Stage Development, H1 2013 64
Comparative Analysis by Early Clinical Stage Development, H1 2013 65
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 66
Products under Development by Companies, H1 2013 67
Products under Development by Companies, H1 2013 (Contd..1) 68
Products under Development by Companies, H1 2013 (Contd..2) 69
Products under Development by Companies, H1 2013 (Contd..3) 70
Products under Development by Companies, H1 2013 (Contd..4) 71
Products under Development by Companies, H1 2013 (Contd..5) 72
Products under Development by Companies, H1 2013 (Contd..6) 73
Products under Development by Companies, H1 2013 (Contd..7) 74
Products under Development by Companies, H1 2013 (Contd..8) 75
Products under Development by Companies, H1 2013 (Contd..9) 76
Products under Development by Companies, H1 2013 (Contd..10) 77
Products under Development by Companies, H1 2013 (Contd..11) 78
Products under Development by Companies, H1 2013 (Contd..12) 79
Products under Development by Companies, H1 2013 (Contd..13) 80
Products under Development by Companies, H1 2013 (Contd..14) 81
Products under Development by Companies, H1 2013 (Contd..15) 82
Products under Development by Companies, H1 2013 (Contd..16) 83
Products under Development by Companies, H1 2013 (Contd..17) 84
Products under Development by Companies, H1 2013 (Contd..18) 85
Products under Development by Companies, H1 2013 (Contd..19) 86
Products under Development by Companies, H1 2013 (Contd..20) 87
Products under Development by Companies, H1 2013 (Contd..21) 88
Products under Development by Companies, H1 2013 (Contd..22) 89
Products under Development by Companies, H1 2013 (Contd..23) 90
Products under Development by Companies, H1 2013 (Contd..24) 91
Products under Development by Companies, H1 2013 (Contd..25) 92
Products under Development by Companies, H1 2013 (Contd..26) 93
Products under Development by Companies, H1 2013 (Contd..27) 94
Products under Development by Companies, H1 2013 (Contd..28) 95
Products under Development by Companies, H1 2013 (Contd..29) 96
Products under Development by Companies, H1 2013 (Contd..30) 97
Products under Development by Companies, H1 2013 (Contd..31) 98
Products under Development by Companies, H1 2013 (Contd..32) 99
Products under Development by Companies, H1 2013 (Contd..33) 100
Products under Development by Companies, H1 2013 (Contd..34) 101
Products under Development by Companies, H1 2013 (Contd..35) 102
Products under Development by Companies, H1 2013 (Contd..36) 103
Products under Development by Companies, H1 2013 (Contd..37) 104
Products under Development by Companies, H1 2013 (Contd..38) 105
Products under Development by Companies, H1 2013 (Contd..39) 106
Products under Development by Companies, H1 2013 (Contd..40) 107
Products under Development by Companies, H1 2013 (Contd..41) 108
Products under Investigation by Universities/Institutes, H1 2013 109
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 110
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 111
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 112
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 113
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 114
Bristol-Myers Squibb Company, H1 2013 115
Baxter International Inc., H1 2013 116
Johnson and Johnson, H1 2013 117
Boehringer Ingelheim GmbH, H1 2013 118
F. Hoffmann-La Roche Ltd., H1 2013 119
Photocure ASA, H1 2013 120
Helix BioPharma Corp., H1 2013 121
Vical Incorporated, H1 2013 122
United Therapeutics Corporation, H1 2013 123
Medgenics Inc., H1 2013 124
Valeant Pharmaceuticals International, H1 2013 125
Sanofi-Aventis, H1 2013 126
GlaxoSmithKline plc, H1 2013 127
Tekmira Pharmaceuticals Corp., H1 2013 128
Genentech, Inc., H1 2013 129
Antigenics, Inc., H1 2013 130
Inovio Biomedical Corporation, H1 2013 131
Idenix Pharmaceuticals, Inc., H1 2013 132
Isis Pharmaceuticals, Inc., H1 2013 133
Gilead Sciences, Inc., H1 2013 134
Daiichi Sankyo Company, Ltd, H1 2013 135
Merck and Co., Inc., H1 2013 136
United Biomedical, Inc., H1 2013 137
Lentigen Corporation, H1 2013 138
Bioneer Corporation, H1 2013 139
BioLineRx, Ltd., H1 2013 140
MediGene AG, H1 2013 141
Celltrion, Inc., H1 2013 142
Nanotherapeutics, Inc., H1 2013 143
Biological E. Limited, H1 2013 144
Biotron Limited, H1 2013 145
Novartis AG, H1 2013 146
Isotechnika Pharma Inc., H1 2013 147
Aphios Corporation, H1 2013 148
Achillion Pharmaceuticals, Inc., H1 2013 149
Astellas Pharma Inc., H1 2013 150
Chong Kun Dang Pharmaceutical, H1 2013 151
Chugai Pharmaceutical Co. Ltd, H1 2013 152
InterMune, Inc., H1 2013 153
Novavax, Inc., H1 2013 154
Ono Pharmaceutical Co., Ltd., H1 2013 155
Pfizer Inc., H1 2013 156
SuperGen, Inc., H1 2013 157
Toyama Chemical Co. Ltd, H1 2013 158
Vertex Pharmaceuticals Incorporated, H1 2013 159
Genmab A/S, H1 2013 160
Avexa Limited, H1 2013 161
Koronis Pharmaceuticals, Inc., H1 2013 162
Santaris Pharma A/S, H1 2013 163
Aduro BioTech, H1 2013 164
Alfacell Corporation, H1 2013 165
CEL-SCI Corporation, H1 2013 166
AVI BioPharma Inc., H1 2013 167
Crucell N.V., H1 2013 168
Celgene Corporation, H1 2013 169
Geron Corporation, H1 2013 170
Zosano Pharma, Inc., H1 2013 171
4SC AG, H1 2013 172
GeoVax Labs, Inc., H1 2013 173
Hemispherx Biopharma, Inc., H1 2013 174
Agenix Limited, H1 2013 175
Enzo Biochem, Inc., H1 2013 176
Immtech Pharmaceuticals, Inc., H1 2013 177
Can-Fite BioPharma Ltd., H1 2013 178
Intercell AG, H1 2013 179
Arrowhead Research Corporation, H1 2013 180
Ligand Pharmaceuticals Incorporated, H1 2013 181
Medicago Inc., H1 2013 182
Medivir AB, H1 2013 183
Bio-Bridge Science, Inc., H1 2013 184
Benitec Ltd., H1 2013 185
BioDiem Ltd, H1 2013 186
Mymetics Corporation, H1 2013 187
NanoViricides, Inc., H1 2013 188
NexMed, Inc., H1 2013 189
Novelos Therapeutics, Inc., H1 2013 190
Nutra Pharma Corporation, H1 2013 191
ConjuChem Biotechnologies Inc., H1 2013 192
Peregrine Pharmaceuticals, Inc., H1 2013 193
Critical Outcome Technologies Inc., H1 2013 194
CytoGenix, Inc., H1 2013 195
Amarillo Biosciences, Inc., H1 2013 196
BioCryst Pharmaceuticals, Inc., H1 2013 197
Flamel Technologies S.A., H1 2013 198
Emisphere Technologies, Inc., H1 2013 199
SIGA Technologies, Inc., H1 2013 200
Dynavax Technologies Corporation, H1 2013 201
Tolerx, Inc., H1 2013 202
Starpharma Holdings Limited, H1 2013 203
Transgene SA, H1 2013 204
Prima BioMed Limited, H1 2013 205
Immuron Limited, H1 2013 206
Lipoxen PLC, H1 2013 207
Miraca Holdings Inc., H1 2013 208

List of Figures

Number of Products under Development for Viral Infections, H1 2013 33
Products under Development for Viral Infections - Comparative Analysis, H1 2013 34
Products under Development by Companies, H1 2013 35
Products under Investigation by Universities/Institutes, H1 2013 58
Late Stage Products, H1 2013 63
Mid Clinical Stage Products, H1 2013 64
Early Clinical Stage Products, H1 2013 65
Discovery and Pre-Clinical Stage Products, H1 2013 66
Assessment by Monotherapy Products, H1 2013 372
Assessment by Combination Products, H1 2013 373
Assessment by Route of Administration, H1 2013 374
Assessment by Stage and Route of Administration, H1 2013 375
Assessment by Molecule Type, H1 2013 377
Assessment by Stage and Molecule Type, H1 2013 378

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.